Page 76 - Tyrosine-Based Bioconjugations - Jorick Bruins

Chapter 4
4.5. References
(1) Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., and Chatal, J. F., Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 2006, 24 (5), 823-34.
(2) Wu, A. M., and Olafsen, T., Antibodies for molecular imaging of cancer. Cancer J. 2008, 14 (3), 191-7.
(3) Chari, R. V., Miller, M. L., and Widdison, W. C., Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. 2014, 53 (15), 3796-827.
(4) Beck, A., Goetsch, L., Dumontet, C., and Corvaia, N., Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discovery 2017, 16 (5), 315-37.
(5) Chang, L., Li, J., and Wang, L., Immuno-PCR: An ultrasensitive immunoassay for biomolecular detection. Anal. Chim. Acta 2016, 910, 12-24.
(6) Boutureira, O., and Bernardes, G. J. L., Advances in Chemical Protein Modification. Chem. Rev. 2015, 115 (5), 2174-95.
(7) Oliveira, B. L., Guo, Z., and Bernardes, G. J. L., Inverse electron demand Diels-Alder reactions in chemical biology. Chem. Soc. Rev. 2017, 46 (16), 4895-950.
(8) de Graaf, A. J., Kooijman, M., Hennink, W. E., and Mastrobattista, E., Nonnatural amino acids for site-specific protein conjugation. Bioconjugate Chem. 2009, 20 (7), 1281-95.
(9) Lang, K., and Chin, J. W., Cellular Incorporation of Unnatural Amino Acids and Bioorthogonal Labeling of Proteins. Chem. Rev. 2014, 114 (9), 4764-806.
(10) Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., et al., Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (40), 16101-6.
(11) Zimmerman, E. S., Heibeck, T. H., Gill, A., Li, X. F., Murray, C. J., Madlansacay, M. R., Tran, C., Uter, N. T., Yin, G., Rivers, P. J., et al., Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System. Bioconjugate Chem. 2014, 25 (2), 351-61.
(12) Koniev, O., and Wagner, A., Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation. Chem. Soc. Rev. 2015, 44 (15), 5495-551.
(13) van Berkel, S. S., and van Delft, F. L., Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discov Today: Technol. 2018, 30, 3-10.
(14) Bartels, L., Ploegh, H. L., Spits, H., and Wagner, K., Preparation of bispecific antibody- protein adducts by site-specific chemo-enzymatic conjugation. Methods 2019, 154, 93- 101.
(15) Bartels, L., de Jong, G., Gillissen, M. A., Yasuda, E., Kattler, V., Bru, C., Fatmawati, C., van Hal-van Veen, S. E., Cercel, M. G., Moiset, G., et al., A chemo-enzymatically linked bispecific antibody retargets T cells to a sialylated epitope on CD43 in acute myeloid leukemia. Cancer Res 2019.
(16) Grünewald, J., Klock, H. E., Cellitti, S. E., Bursulaya, B., McMullan, D., Jones, D. H., Chiu, H.- P., Wang, X., Patterson, P., Zhou, H., et al., Efficient Preparation of Site-Specific Antibody Drug Conjugates Using Phosphopantetheinyl Transferases. Bioconjugate Chem. 2015, 26 (12), 2554-62.
74